What do we know about the comparative immunogenicity profiles of originator anti-TNF vs biosimilars for infliximab? Do we have evidence confirming the safety of biosimilars for patients with RA?

What do we know about the comparative immunogenicity profiles of originator anti-TNF vs biosimilars for infliximab? Do we have evidence confirming the safety of biosimilars for patients with RA?

What do we know about the comparative immunogenicity profiles of originator anti-TNF vs biosimilars for infliximab? Do we have sufficient evidence confirming the safety of biosimilars for patients with RA?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA